A Phase 3 interventional study of Tezepelumab and Placebo in Asthma, sponsored by AstraZeneca. Terminated at 64 sites in 12 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-18.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing tezepelumab in Asthma — 7 open to participants now, 8 under way, 5 of them phase 3. tezepelumab · Asthma.
Among the 28 studies testing tezepelumab in Asthma, this one is the 14th largest by enrollment, is one of 4 that started in 2022, is one of 16 in phase 3, and was the 18th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →7 of the 28 studies testing tezepelumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
University of Alberta · Sites in Canada
Ages 18–55
AstraZeneca · Sites in China
Ages 12–80
AstraZeneca · Sites in United States, Argentina, Brazil and 19 more countries
Ages 5–11
Qianfoshan Hospital · Sites in China
Ages 18–75
Qilu Pharmaceutical Co., Ltd.
Ages 18–80
By country, each count listing its studies:
tezepelumab: first FDA approval 2021 (TEZSPIRE), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 4 started in 2022.
This study's enrollment of 125 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 121 across the 28 interventional studies. Of the 19 that completed or were terminated, 15 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 28 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
359 studies in Asthma by AstraZeneca: 19 open now, 28 under way, 8 of them phase 3. Of 330 finished, 129 (39%) have results posted.
Among the 359 studies in Asthma by AstraZeneca, this one is the 138th largest by enrollment of the 248 interventional ones that give a count, is one of 13 that started in 2022, is one of 121 in phase 3, and was the 293rd registered.
AstraZeneca’s Asthma studies by the year they started, since 1996.
3 of the studies testing tezepelumab in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06473779Phase 3AstraZenecaOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | 2027-06-25 |
| NCT06705764University of AlbertaTezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA) | 2026-11 |
| NCT07757841Qianfoshan HospitalReal-World Effectiveness of Tezepelumab in Allergic Bronchopulmonary Aspergillosis | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 28 studies testing tezepelumab in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 359 in Asthma:
This tab as a report to print or save as PDF → With an account.
A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled 28-week Phase 3 Efficacy and Safety Study of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma
This is a multicentre, randomised, double-blind, placebo controlled, parallel group study designed to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma treated with maintenance OCS in combination with high dose inhaled corticosteroids (ICS) and long-acting β2 agonists (LABA), with or without other asthma controller therapies. Approximately 207 subjects will be randomized globally. Subjects will receive tezepelumab, or placebo, administered via subcutaneous injection using the accessorized pre-filled syringe (APFS), over a 28-week treatment period. The study also includes a post-treatment follow-up period of 12 weeks.
Main inclusion criteria:
Evidence of asthma as documented by either:
a)Post-BD responsiveness test result: FEV1 ≥12% and ≥200 mL documented either in the previous 60 months prior to or at Visit 1 or at Visit 2 or at Visit 3; OR b)Airway hyperresponsiveness (methacholine: provocative concentration that causes a positive reaction [PC20] of \<8 mg/mL) documented in the 60 months prior to Visit 1.
Other inclusion criteria per protocol apply.
Main exclusion criteria
Other exclusion criteria per protocol apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tezepelumab subcutaneous injection, in an accessorised pre-filled syringe.
Biological: Tezepelumab
Placebo subcutaneous injection, in an accessorised pre-filled syringe.
Other: Placebo
Tezepelumab subcutaneous injection
Placebo subcutaneous injection
Proportion of Subjects by Categorised Percent Reduction From Baseline in the Daily Maintenance OCS Dose at Week 28 Whilst Maintaining Asthma Control.
Proportion of subjects by categorised percent reduction from baseline at Week 28. Percent change from baseline is defined as {final dose-baseline dose)/baseline dose}\*100%, and the categories of percent change from baseline in daily OCS dose are defined as: ≥90% to ≤100% reduction, ≥75% to \<90% reduction, ≥50% to \<75% reduction, \>0% to \<50% reduction, and, no change or any increase.
Time frame: Baseline to Week 28
Change From Baseline in Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in 1 Second (FEV1) at Week 28
Change from baseline in pre-BD FEV1 at Week 28. FEV1 is defined as the volume of air exhaled from the lungs in the first second of a forced expiration.
Time frame: Baseline to Week 28
Proportion of Subjects With 100% Reduction From Baseline in Daily OCS Dose at Week 28
Proportion of subjects with 100% reduction from baseline in daily OCS dose at Week 28. Percent change from baseline is defined as {(final dose-baseline dose)/baseline dose}\*100%.
Time frame: Baseline to Week 28
Proportion of Subjects With Daily OCS Dose ≤5 mg at Week 28
Proportion of subjects with daily OCS dose ≤5 mg at Week 28.
Time frame: Week 28
Proportion of Subjects With ≥50% Reduction From Baseline in Daily OCS Dose at Week 28
Proportion of subjects with ≥50% reduction from baseline in daily OCS dose at Week 28. Percent change from baseline is defined as {(final dose-baseline dose)/baseline dose}\*100%.
Time frame: Baseline to Week 28
Annualised Asthma Exacerbation Rate (AAER) Over 28 Weeks
The annualized exacerbation rate is based on exacerbations reported by the investigator in the eCRF over 28 weeks.
Time frame: Baseline to Week 28
Proportion of Subjects With >= 1 Asthma Exacerbation
Time to first asthma exacerbation, presented as proportion of subjects with at least one asthma exacerbation as reported by the investigator in the eCRF
Time frame: Baseline to Week 28
Change From Baseline in Asthma Control Questionnaire 6 (ACQ-6) Score at Week 28
Change from baseline in ACQ-6 as compared to placebo at Week 28. The ACQ-6 captures asthma symptoms and short-acting β2-agonist use via subject-report. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The ACQ-6 score is the mean of the responses.
Time frame: Baseline to Week 28
Change From Baseline in Weekly Mean Home Peak Expiratory Flow (PEF) (Morning and Evening) at Week 28
Change from baseline in weekly mean morning and evening peak expiratory flow (PEF) as compared to placebo at Week 28. Home PEF testing will be performed by the subject in the morning upon awakening and in the evening at bedtime using an electronic, hand-held spirometer. Each timepoint is calculated as weekly.
Time frame: Baseline to Week 28
Change From Baseline in Standardized Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(s)+12) Total Score at Week 28
Change from baseline in AQLQ(S)+12 as compared to placebo at Week 28. The AQLQ(S)+12 is a questionnaire that measures the health-related quality of life experienced by asthma subjects. The total score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment).
Time frame: Baseline to Week 28
Change From Baseline in St George's Respiratory Questionnaire (SGRQ) Score at Week 28
Change from baseline in SGRQ as compared to placebo at Week 28. The questionnaire is divided into 2 parts: part 1 consists of 8 items pertaining to the severity of respiratory symptoms in the preceding 4 weeks; part 2 consists of 42 items related to the daily activity and psychosocial impacts of the individual's respiratory condition. The total score indicates the impact of disease on overall health status. This total score is expressed as a percentage of overall impairment, in which 100 represents the worst possible health status and 0 indicates the best possible health status.
Time frame: Baseline to Week 28
Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) at Week 28
Change from baseline in fractional exhaled nitric oxide (FeNO) at Week 28.
Time frame: Baseline to Week 28
Change From Baseline in Peripheral Blood Eosinophils at Week 28
Change from baseline in blood eosinophil counts at Week 28.
Time frame: Baseline to Week 28
Change From Baseline in Total Serum Immunoglobulin E (IgE) at Week 28
Change from baseline in total serum IgE at Week 28.
Time frame: Baseline to Week 28
PK: Serum Trough Concentrations at Week 0, 12 and 28
Pharmacokinetics samples are collected at baseline and at Week 12 prior to study intervention administration, and at Week 28 (End of Treatment visit).
Time frame: Baseline, Week 12 and Week 28
Immunogenicity: Incidence of Anti-drug Antibodies (ADA) at Week 0, 12, 28, and 40
Immunogenicity samples are collected at baseline and at Week 12 prior to study intervention administration, at Week 28 (End of Treatment visit) and at Week 40 (Follow-up visit). Persistently positive is defined as positive at \>=2 post baseline assessments (with \>=16 weeks between the first and the last positive) or positive at last post baseline assessment. Transiently positive is defined as having at least one post baseline ADA positive assessment and not fulfilling the conditions of persistently positive. Treatment boosted ADA defined as baseline positive ADA that was boosted to a 4 fold or higher level following treatment. Treatment emergent ADA defined as sum of treatment induced ADA and treatment boosted ADA.
Time frame: Baseline to Week 40
The study was conducted at 64 centres in 12 countries. Between 9AUG2022 and 29NOV2024, 250 subjects were screened; 125 were randomized and treated, and 125 were not randomized mainly due to screen failures. Four participants (1 tezepelumab, 2 placebo, 1 screen failure) from one site were excluded for quality issues, so 122 randomized participants were analysed. The sponsor terminated the study early due to recruitment challenges.
| Milestone | Tezepelumab | Placebo |
|---|---|---|
| Started | 84 | 41 |
| Completed | 59 | 30 |
| Not completed | 25 | 11 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Death | 2 | 1 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Study terminated by sponsor | 18 | 7 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: End of study due to low compliance by participant | 0 | 1 |
| Withdrew: Site quality issues | 1 | 2 |
Proportion of subjects by categorised percent reduction from baseline at Week 28. Percent change from baseline is defined as {final dose-baseline dose)/baseline dose}\*100%, and the categories of percent change from baseline in daily OCS dose are defined as: ≥90% to ≤100% reduction, ≥75% to \<90% reduction, ≥50% to \<75% reduction, \>0% to \<50% reduction, and, no change or any increase.
| Participants | Tezepelumab | Placebo |
|---|---|---|
| >=90% to <=100% reduction | 30 | 8 |
| >=75% to <90% reduction | 7 | 3 |
| >=50% to <75% reduction | 20 | 6 |
| >0% to <50% reduction | 12 | 6 |
| no change or any increase | 14 | 16 |
Change from baseline in pre-BD FEV1 at Week 28. FEV1 is defined as the volume of air exhaled from the lungs in the first second of a forced expiration.
| Litre | Tezepelumab | Placebo |
|---|---|---|
| Change From Baseline in Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in 1 Second (FEV1) at Week 28 | 0.240 ± 0.498 | -0.019 ± 0.310 |
Proportion of subjects with 100% reduction from baseline in daily OCS dose at Week 28. Percent change from baseline is defined as {(final dose-baseline dose)/baseline dose}\*100%.
| Participants | Tezepelumab | Placebo |
|---|---|---|
| Proportion of Subjects With 100% Reduction From Baseline in Daily OCS Dose at Week 28 | 29 | 8 |
Proportion of subjects with daily OCS dose ≤5 mg at Week 28.
| Participants | Tezepelumab | Placebo |
|---|---|---|
| Proportion of Subjects With Daily OCS Dose ≤5 mg at Week 28 | 49 | 15 |
Proportion of subjects with ≥50% reduction from baseline in daily OCS dose at Week 28. Percent change from baseline is defined as {(final dose-baseline dose)/baseline dose}\*100%.
| Participants | Tezepelumab | Placebo |
|---|---|---|
| Proportion of Subjects With ≥50% Reduction From Baseline in Daily OCS Dose at Week 28 | 57 | 17 |
The annualized exacerbation rate is based on exacerbations reported by the investigator in the eCRF over 28 weeks.
| Events per year | Tezepelumab | Placebo |
|---|---|---|
| Annualised Asthma Exacerbation Rate (AAER) Over 28 Weeks | 0.65 | 1.98 |
Time to first asthma exacerbation, presented as proportion of subjects with at least one asthma exacerbation as reported by the investigator in the eCRF
| Participants | Tezepelumab | Placebo |
|---|---|---|
| Proportion of Subjects With >= 1 Asthma Exacerbation | 25 | 23 |
Change from baseline in ACQ-6 as compared to placebo at Week 28. The ACQ-6 captures asthma symptoms and short-acting β2-agonist use via subject-report. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The ACQ-6 score is the mean of the responses.
| Score on a scale | Tezepelumab | Placebo |
|---|---|---|
| Change From Baseline in Asthma Control Questionnaire 6 (ACQ-6) Score at Week 28 | -1.25 ± 1.14 | -0.59 ± 1.09 |
Change from baseline in weekly mean morning and evening peak expiratory flow (PEF) as compared to placebo at Week 28. Home PEF testing will be performed by the subject in the morning upon awakening and in the evening at bedtime using an electronic, hand-held spirometer. Each timepoint is calculated as weekly.
| L/min | Tezepelumab | Placebo |
|---|---|---|
| Weekly mean morning PEF | 27.4 ± 65.0 | -10.6 ± 56.9 |
| Weekly mean evening PEF | 24.3 ± 70.3 | -12.4 ± 51.7 |
Change from baseline in AQLQ(S)+12 as compared to placebo at Week 28. The AQLQ(S)+12 is a questionnaire that measures the health-related quality of life experienced by asthma subjects. The total score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment).
| Scores on a scale | Tezepelumab | Placebo |
|---|---|---|
| Change From Baseline in Standardized Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(s)+12) Total Score at Week 28 | 1.42 ± 1.33 | 0.44 ± 1.20 |
Change from baseline in SGRQ as compared to placebo at Week 28. The questionnaire is divided into 2 parts: part 1 consists of 8 items pertaining to the severity of respiratory symptoms in the preceding 4 weeks; part 2 consists of 42 items related to the daily activity and psychosocial impacts of the individual's respiratory condition. The total score indicates the impact of disease on overall health status. This total score is expressed as a percentage of overall impairment, in which 100 represents the worst possible health status and 0 indicates the best possible health status.
| Scores on a scale | Tezepelumab | Placebo |
|---|---|---|
| Change From Baseline in St George's Respiratory Questionnaire (SGRQ) Score at Week 28 | -22.09 ± 24.04 | -6.14 ± 24.29 |
Change from baseline in fractional exhaled nitric oxide (FeNO) at Week 28.
| ppb | Tezepelumab | Placebo |
|---|---|---|
| Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) at Week 28 | -14.0 ± 27.0 | 2.0 ± 21.9 |
Change from baseline in blood eosinophil counts at Week 28.
| cells/μL | Tezepelumab | Placebo |
|---|---|---|
| Change From Baseline in Peripheral Blood Eosinophils at Week 28 | -112.9 ± 314.2 | -79.2 ± 279.2 |
Change from baseline in total serum IgE at Week 28.
| IU/mL | Tezepelumab | Placebo |
|---|---|---|
| Change From Baseline in Total Serum Immunoglobulin E (IgE) at Week 28 | -50.006 ± 520.663 | -8.107 ± 195.584 |
Pharmacokinetics samples are collected at baseline and at Week 12 prior to study intervention administration, and at Week 28 (End of Treatment visit).
| μg/mL | Tezepelumab | Placebo |
|---|---|---|
| Week 0 | 0 ± 0 | — |
| Week 12 | 18.371 ± 50.59 | — |
| Week 28 | 19.849 ± 55.23 | — |
Immunogenicity samples are collected at baseline and at Week 12 prior to study intervention administration, at Week 28 (End of Treatment visit) and at Week 40 (Follow-up visit). Persistently positive is defined as positive at \>=2 post baseline assessments (with \>=16 weeks between the first and the last positive) or positive at last post baseline assessment. Transiently positive is defined as having at least one post baseline ADA positive assessment and not fulfilling the conditions of persistently positive. Treatment boosted ADA defined as baseline positive ADA that was boosted to a 4 fold or higher level following treatment. Treatment emergent ADA defined as sum of treatment induced ADA and treatment boosted ADA.
| Participants | Tezepelumab | Placebo |
|---|---|---|
| ADA positive at baseline and/or post-baseline (ADA prevalence) [a] | 6 | 2 |
| TE-ADA positive (ADA incidence) [b] | 3 | 1 |
| Treatment-induced ADA positive [b] | 3 | 1 |
| Treatment-boosted ADA positive [b] | 0 | 0 |
| Non-TE-ADA positive [b] | 3 | 1 |
| Both baseline and post-baseline positive [b] | 0 | 0 |
| Only baseline positive [c] | 3 | 1 |
| ADA persistently positive [b] | 2 | 0 |
| ADA transiently positive [b] | 1 | 1 |
| nAb positive at baseline and/or post-baseline (nAb prevalence) [a] | 1 | 0 |
| Treatment-induced nAb positive (nAb incidence) [b] | 1 | 0 |
Collected over From the date of first dose of study intervention throughout the treatment period and including the follow-up period (i.e. up to Week 40).. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tezepelumab | 2/83 (2.4%) | 7/83 (8.4%) | 33/83 (39.8%) |
| Placebo | 1/39 (2.6%) | 5/39 (12.8%) | 21/39 (53.8%) |
| Event | Tezepelumab | Placebo |
|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 2/83 | 3/39 |
| TracheobronchitisInfections and infestations | 0/83 | 1/39 |
| Cardiac arrestCardiac disorders | 0/83 | 1/39 |
| Soft tissue infectionInfections and infestations | 1/83 | 0/39 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/83 | 0/39 |
| MeningiomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/83 | 0/39 |
| Plasma cell myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/83 | 0/39 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/83 | 0/39 |
| Sudden cardiac deathGeneral disorders | 1/83 | 0/39 |
| PneumoniaInfections and infestations | 1/83 | 0/39 |
| Event | Tezepelumab | Placebo |
|---|---|---|
| NasopharyngitisInfections and infestations | 11/83 | 7/39 |
| HeadacheNervous system disorders | 2/83 | 4/39 |
| BronchitisInfections and infestations | 2/83 | 4/39 |
| Upper respiratory tract infectionInfections and infestations | 7/83 | 3/39 |
| Urinary tract infectionInfections and infestations | 5/83 | 2/39 |
| SinusitisInfections and infestations | 2/83 | 2/39 |
| AnxietyPsychiatric disorders | 1/83 | 2/39 |
| Oral candidiasisInfections and infestations | 3/83 | 2/39 |
| FallInjury, poisoning and procedural complications | 3/83 | 1/39 |
| Limb injuryInjury, poisoning and procedural complications | 3/83 | 0/39 |
| Age, Categorical(Participants) | Tezepelumab | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 67 | 32 | 99 |
| >=65 years | 16 | 7 | 23 |
| Age, Continuous(Years) | Tezepelumab | Placebo | Total |
|---|---|---|---|
| Mean | 51.6 ± 12.7 | 53.6 ± 13.0 | 52.2 ± 12.8 |
| Sex: Female, Male(Participants) | Tezepelumab | Placebo | Total |
|---|---|---|---|
| Female | 65 | 27 | 92 |
| Male | 18 | 12 | 30 |
| Race/Ethnicity, Customized(Participants) | Tezepelumab | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 3 | 1 | 4 |
| Asian | 14 | 5 | 19 |
| Black or African American | 1 | 1 | 2 |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 0 |
| White | 42 | 25 | 67 |
| Other/Multiple race | 21 | 6 | 27 |
| Missing | 2 | 1 | 3 |
| Race/Ethnicity, Customized(Participants) | Tezepelumab | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 42 | 21 | 63 |
| Not Hispanic or Latino | 41 | 18 | 59 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluatedas per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes,indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level datain an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access.For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Aug 2022 to primary completion in Mar 2025, 31 months.
Results were first posted in Jun 2026, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tezepelumab